Literature DB >> 28066966

Updating the neuropsychological test system in Japan for the elderly and in a modern touch screen tablet society by resetting the cut-off values.

Takumi Kawaguchi1, Mika Konishi2, Akinobu Kato3,4, Motoichiro Kato2, Yohei Kooka3, Kei Sawara3, Ryujin Endo3, Takuji Torimura1, Kazuyuki Suzuki3,5, Yasuhiro Takikawa3.   

Abstract

AIM: Covert hepatic encephalopathy is frequently seen in cirrhotic patients. This condition can be diagnosed by a computerized neuropsychological test system (NPT); however, NPT has not been updated for approximately two decades in Japan. The aim of this study is to update the NPT to be more suitable for both the elderly and modern society by resetting of cut-off values.
METHODS: We enrolled 367 healthy subjects aged between 40 and 79 years old between 2003 and 2010. The NPT consists of the following eight tests: number connection tests (NCT)-A and -B, a figure position test, a digit symbol test, a block design test, and reaction time tests (RTT)-A, -B, and -C. All subjects were classified into eight groups (5-year quartile ranges from 40 to 79 years old), and the cut-off value for each test was compared to the former cut-off value (NPT version 1).
RESULTS: In all eight tests, most of the cut-off values were different from those in NPT version 1. The difference was minimal in RTT-A, RTT-B, and RTT-C. However, the difference was evident in the NCT-A, NCT-B, digit symbol test, and block design test. In particular, a 57.8-s decrease in the cut-off value was seen in the 65-69-year-old group for the NCT-B test (71.3 s vs. 129.1 s).
CONCLUSIONS: We updated the NPT by covering subjects aged 40-79 years and resetting the cut-off values. Thus, the updated NPT is an elderly and modern subject-compliant application. This update may improve the diagnostic ability of covert hepatic encephalopathy in contemporary cirrhotic patients.
© 2017 The Japan Society of Hepatology.

Entities:  

Keywords:  cognition; covert hepatic encephalopathy; liver cirrhosis; neuropsychiatric test

Year:  2017        PMID: 28066966     DOI: 10.1111/hepr.12864

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  8 in total

1.  Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.

Authors:  Masato Nakai; Goki Suda; Koji Ogawa; Sonoe Yoshida; Shunichi Hosoda; Akinori Kubo; Yoshimasa Tokuchi; Takashi Kitagataya; Ren Yamada; Taku Shigesawa; Masatsugu Ohara; Takuya Sho; Kenichi Morikawa; Naoya Sakamoto
Journal:  PLoS One       Date:  2022-07-01       Impact factor: 3.752

2.  Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.

Authors:  Kosuke Kaji; Hiroaki Takaya; Soichiro Saikawa; Masanori Furukawa; Shinya Sato; Hideto Kawaratani; Mitsuteru Kitade; Kei Moriya; Tadashi Namisaki; Takemi Akahane; Akira Mitoro; Hitoshi Yoshiji
Journal:  World J Gastroenterol       Date:  2017-12-21       Impact factor: 5.742

3.  Small Intestinal Bacterial Overgrowth Diagnosed by a Breath Test and Improved by Rifaximin in a Patient with Hepatic Encephalopathy and Alcoholic Liver Cirrhosis.

Authors:  Akira Sakamaki; Kunihiko Yokoyama; Fusako Yamazaki; Hiroteru Kamimura; Kenya Kamimura; Masaaki Takamura; Junji Yokoyama; Shuji Terai
Journal:  Intern Med       Date:  2020-04-23       Impact factor: 1.271

4.  Rifaximin-altered gut microbiota components associated with liver/neuropsychological functions in patients with hepatic encephalopathy: An exploratory data analysis of phase II/III clinical trials.

Authors:  Takumi Kawaguchi; Fumitaka Suzuki; Masatoshi Imamura; Naoya Murashima; Mikio Yanase; Tetsuya Mine; Masaki Fujisawa; Ikuya Sato; Hitoshi Yoshiji; Kiwamu Okita; Kazuyuki Suzuki
Journal:  Hepatol Res       Date:  2019-02-01       Impact factor: 4.288

5.  Association between serum albumin and cognitive dysfunction in hepatic encephalopathy: An exploratory data analysis.

Authors:  Kosuke Kaji; Kiwamu Okita; Kazuyuki Suzuki; Ikuya Sato; Masaki Fujisawa; Hitoshi Yoshiji
Journal:  JGH Open       Date:  2020-12-07

6.  Hydrogen-producing small intestinal bacterial overgrowth is associated with hepatic encephalopathy and liver function.

Authors:  Kunihiko Yokoyama; Akira Sakamaki; Kazuya Takahashi; Takumi Naruse; Chihiro Sato; Yuzo Kawata; Kentaro Tominaga; Hiroyuki Abe; Hiroki Sato; Atsunori Tsuchiya; Kenya Kamimura; Masaaki Takamura; Junji Yokoyama; Shuji Terai
Journal:  PLoS One       Date:  2022-02-25       Impact factor: 3.240

7.  Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients.

Authors:  Kosuke Kaji; Soichiro Saikawa; Hiroaki Takaya; Yukihisa Fujinaga; Masanori Furukawa; Koh Kitagawa; Takahiro Ozutsumi; Daisuke Kaya; Yuki Tsuji; Yasuhiko Sawada; Hideto Kawaratani; Kei Moriya; Tadashi Namisaki; Takemi Akahane; Akira Mitoro; Hitoshi Yoshiji
Journal:  Antibiotics (Basel)       Date:  2020-03-29

8.  Impaired brain function improved by L-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy.

Authors:  Hiroyuki Nakanishi; Yuka Hayakawa; Youhei Kubota; Masayuki Kurosaki; Leona Osawa; Kento Inada; Sakura Kirino; Koji Yamashita; Shuhei Sekiguchi; Mao Okada; Wang Wan; Mayu Higuchi; Kenta Takaura; Chiaki Maeyashiki; Shun Kaneko; Nobuharu Tamaki; Yutaka Yasui; Takamasa Noda; Kaoru Nakanishi; Kaoru Tsuchiya; Jun Itakura; Yuka Takahashi; Namiki Izumi
Journal:  Sci Rep       Date:  2020-08-11       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.